CLINICAL AND INSTRUMENTAL FEATURES OF CORONARY HEART DISEASE IN PATIENTS WITH COMORBID CONDITIONS
Keywords:
Arterial hypertension, diabetes mellitus, coronary heart disease, ECG, myocardial infarction, cardiovascular diseasesAbstract
Arterial hypertension and type 2 diabetes are common comorbidities. In patients with diabetes mellitus, arterial hypertension occurs twice as often as in patients without diabetes.
Purpose of the study: to reveal the clinical and instrumental features of the course of coronary artery disease in patients with arterial hypertension in combination with type II diabetes mellitus.
Materials and methods of research: Particular attention was paid to the clinical examination of patients, which included the collection of complaints, anamnesis, and physical examination. The diagnosis of postinfarction cardiosclerosis was made on the basis of anamnestic data, ECG data, Holter monitoring and echocardiography. The instrumental study included ECG, echocardiography, determination of the thickness of the intima-media complex of the carotid arteries, X-ray of the chest organs. For persons with HIBS in order to verify ischemia Holter-ECG or stress tests.
Results of the study: the indicators studied by us confirmed that patients with concomitant pathology in the form of type 2 diabetes aggravate the course of the underlying disease. Indicators of ECG monitoring in the concomitant course of DM showed ST segment depression, which allows substantiating the risk of coronary atherosclerosis, revealing hidden forms of chronic coronary artery disease in atypical course of the disease in patients with type 2 diabetes mellitus.
References
Khan S.S., Quaggin S.E. Therapies on the horizon for diabetic kidney disease. Curr Diab Rep. 2015;15:111.
Leung A.A., Daskalopoulou S.S., Dasgupta K. Hypertension Canada's 2017 Guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557–576.
Lewis D.R., Petersen L.K., York A.W. Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques. Cardiovasc Res. 2016;109:283–293.
Yonchuk J.G., Foley J.P., Bolognese B.J. Characterization of the potent, selective Nrf2 activator, 3-(pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2h-chromen-2-one, in cellular and in vivo models of pulmonary oxidative stress. J Pharmacol Exp Ther. 2017;363:114–125.
Sharma A., Rizky L., Stefanovic N. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction. Cardiovasc Diabetol. 2017;16:33.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [e-pub ahead of print]. J Am Coll Cardiol https://doi.org/10.1016/j.jacc.2017.11.006.
Zhuge F., Ni Y., Nagashimada M. DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization. Diabetes. 2016;65:2966–2979.
Ташкенбаева Э. Н., Насырова З. А., Мирзаев Р. З. СТРАТИФИКАЦИЯ ХРОНИЧЕСКОЙ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА В ЗАВИСИМОСТИ ОТ МЕТОДОВ ДИАГНОСТИКИ И ПУТИ ИХ ЛЕЧЕНИЯ //Журнал кардиореспираторных исследований. – 2020. – Т. 1. – №. 3.
Элламонов С. Н. и др. ФАКТОРЫ ПРОГРЕССИРОВАНИЯ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ У БОЛЬНЫХ В КОМОРБИДНОСТИ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА //Журнал кардиореспираторных исследований. – 2021. – Т. 2. – №. 2.
